COVID-19 et maladies bulleuses auto-immunes en 2022

The COVID-19 pandemic is evolving daily, forcing health authorities and physicians to continuously adapt. Patients with autoimmune bullous diseases (ABD), who are often elderly and/or immunocompromised, constitute a population at very high risk of developing a severe form. This study on the impact of COVID-19 on patients with ABD has brought out several key messages: (i) the prescription of rituximab is associated with an increased risk of mortality, contrary to conventional immunosuppressants; (ii) rituximab should only be prescribed for patients in flare-up of their disease, in the absence of any therapeutic alternative; (iii) vaccination of patients and their entourage is still the best solution for reducing the risk of progression to a severe form.